IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v24y2006i3p41-53.html
   My bibliography  Save this article

Effects of Medicaid Access Restrictions on Statin Utilisation for Patients Treated by Physicians Practising in Poor and Minority Neighbourhoods

Author

Listed:
  • Alvin Headen
  • Neal Masia
  • Kirsten Axelsen

Abstract

Objectives: To explore whether Medicaid preferred drug lists (PDL) impact the utilisation of restricted statin (cholesterol-reducing) medication for all Medicaid patients equally or disproportionately impact patients who are treated by doctors prescribing in poor or minority neighbourhoods. Study design: A retrospective, regression-based analysis, using a pharmacy claims database combined with demographic variables derived from census for the zip code of the practising physician. Methods: Changes in the proportion of statin prescriptions filled for off-PDL (restricted) medicines before and after the adoption of a Medicaid PDL were examined in six states (Alabama, Florida, Georgia, Texas, Virginia, West Virginia). Two non-PDL states were used as controls for underlying market dynamics (New York, North Carolina). Demographics of physicians’ neighbourhoods (poverty and ethnicity) were used to examine the variation in prescribing based on the characteristics of physicians’ areas of practice. Results: The decline in the use of restricted prescriptions (off-PDL drugs) after a PDL varied considerably from state to state, with the greatest decline in Florida (97%) and the smallest decline in Texas (65%). There was a statistically significant and positive association between the degree of decline in the use of restricted medications and the share of impoverished households and the share of the minority population in Alabama, Florida and Texas. Conclusion: The analysis indicates that there is considerable variation in the impact of a preferred drug list by state, and that in certain states the prescriptions filled after a PDL adhere more closely to Medicaid-imposed restrictions in poorer or more ethnically diverse neighbourhoods. This could imply that because of the PDL, in these poorer and more ethnically diverse neighbourhoods, there is a greater change in physicians’ prescribing practice, fewer patients receive the restricted medication by prior authorisation, and more patients experience a disruption in their medication regimen and any resultant unintended consequences. This is an area worthy of future exploration, particularly as the oldest and most vulnerable of these patients transition into Medicare part D for their prescription coverage and may experience changes in formulary. Copyright Adis Data Information BV 2006

Suggested Citation

  • Alvin Headen & Neal Masia & Kirsten Axelsen, 2006. "Effects of Medicaid Access Restrictions on Statin Utilisation for Patients Treated by Physicians Practising in Poor and Minority Neighbourhoods," PharmacoEconomics, Springer, vol. 24(3), pages 41-53, December.
    • Handle: RePEc:spr:pharme:v:24:y:2006:i:3:p:41-53
    DOI: 10.2165/00019053-200624003-00004
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200624003-00004
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200624003-00004?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Alvin Headen, 2006. "Medicaid Preferred Drug Lists: Cost Containment and Side Effects," PharmacoEconomics, Springer, vol. 24(3), pages 1-3, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:24:y:2006:i:3:p:41-53. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.